Expanded access policy
ENYO Pharma is developing vonafexor for patients with Alport syndrome through clinical trials, which we believe are the most appropriate and fastest way to make it available to patients.
At this time, ENYO Pharma does not offer expanded access (also known as ‘compassionate use’) to vonafexor outside of its clinical trials. Patients who complete an ENYO Pharma clinical trial may be offered continued treatment under a continuation protocol. We will review the expanded access policy as vonafexor development progresses.
Requests for information: please send an email to clinicaltrial@enyopharma.com. We will acknowledge receipt within 10 business days.
For Trials information: www.clinicaltrials.gov.
Last updated: 18th November 2026